TORONTO — The Winnipeg Jets had payback on their minds and top spot in the National Hockey League in their final game before the holiday break. The Jets made good on both accounts with a 5-2 win against the Toronto Maple Leafs before 18,923 at Scotiabank Arena on Monday. The win avenged a 6-4 home loss to Toronto on Oct. 28, that halted the Jets' eight-game win streak to begin the season. It also pushed the Jets into first overall. "They don't hand out awards at Christmas, but obviously, we're happy," said Jets centre Mark Scheifele, who enjoyed a three-goal, four-point outing. "It's good to get a couple of days off, get recharged and get going for the next half of the season." Surprisingly, the Jets (25-10-1) are only one point ahead of the 36-game pace of 23-9-4 set a year ago. "We've been good from top to bottom and we need everybody in this group," said Kyle O'Connor, who scored the Jets first two goals and helped set up Scheifele for his first of three third-period goals. "I just think our ability to roll over lines and be hungry, and not to be satisfied with anything. We also have taken a day-to-day approach, learning what we can improve on from wins and losses and implementing the adjustments." Besides defeating the Maple Leafs after what transpired in late October, Scheifele had extra motivation after being left off Canada's roster for the 4 Nations Face-Off in February. In the 10 games since Canada's roster was announced, Scheifele has eight goals and 15 points. "You're disappointed, but at the end of the day, you just want to play well for your group of guys," Scheifele said. "There's always a bit of motivation you can draw from in every game. But it's just a matter of playing good for the Winnipeg Jets and controlling what I can control." He also enjoys playing in Toronto, an hour from his hometown of Kitchener. "I love coming to Toronto to have the opportunity to play in front of a lot of friends and family," Scheifele said. "Being so close to home, I get a little extra excited to play here. "I think the biggest thing is we didn't play our best when we played them last. We were excited to get another crack at them and how them the game we can play. All in all, it's a big win for us." MATTHEWS STILL OUT WITH INJURY While the Jets enter the Christmas break with back-to-back wins, the Maple Leafs dropped their second in a row at home without wounded captain Auston Matthews, out with an upper-body injury. "We just have to clean up some things off the rush, the transition part especially against a team that's obviously very good with their top line that takes advantage of time and space," said Maple Leafs centre John Tavares, who scored both Toronto goals. The Maple Leafs have gone 7-4-0 with Matthews on the sidelines this season and 42-23-2 in his career. Toronto was also missing defenceman Chris Tanev, out day-to-day with a lower-body ailment. Tanev missed his first game after skating in the pre-game warm-up. This report by The Canadian Press was first published Dec. 23, 2024. Tim Wharnsby, The Canadian Press
Royal Navy's £3.2billion aircraft carrier stocks up on ammunition and 'increases readiness' as Ukraine military expert says 'World War Three has begun'A group of entrepreneurs hope that a dog-friendly cruise they are planning for next November turns into a recurring event.
On the declaration of 2025 as the «International Year of Peace and Trust»
Neuphoria Completes Re-domiciliation and Successor Listing on NasdaqLast 3 national polls: Election commissioners breached oath of office
Do tree-shaped Reese’s actually taste better than a regular peanut butter cup?
Syrian insurgents reach the capital's suburbs. Worried residents flee and stock up on suppliesDenosumab biosimilar is under clinical development by Samsung Bioepis and currently in Phase III for Post Menopausal Osteoporosis. According to GlobalData, Phase III drugs for Post Menopausal Osteoporosis have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Denosumab biosimilar overview Denosumab biosimilar (SB16) is under development for treatment of osteoporosis and prevention of skeletal related events with advanced malignancies and treatment of giant cell tumour of bone. The therapeutic candidate is a monoclonal antibody, which targets RANK ligand (RANKL). It is administered through subcutaneous route. Samsung Bioepis overview Samsung Bioepis, a subsidiary of Co Ltd, is a biopharmaceutical company. The company develops biosimilar products for immunology, oncology, ophthalmology, hematology, and endocrinology indications. It offers biological drugs for the treatment of Crohn’s disease, ulcerative colitis, psoriasis, cancer, and arthritis. The company is investigating SB12, an Eculizumab biosimilar targeting paroxysmal nocturnal hemoglobinuria; SB15, an Aflibercept biosimilar medicine against neovascular age-related macular degeneration; SB16, a denosumab biosimilar for the treatment of endocrinology disorders. Samsung Bioepis is also evaluating SB17, a Ustekinumab molecule against moderate to severe plaque psoriasis; and SB26 biosimilar to treat gastroenterology indications. Samsung Bioepis is headquartered in Incheon, Seoul, South Korea. For a complete picture of Denosumab biosimilar’s drug-specific PTSR and LoA scores, This content was updated on 12 April 2024 From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s .
The meeting with Collins was closely watched as she is seen as more likely than most of her Republican Senate colleagues to vote against some of Trump’s Cabinet picks.
EXT-608 is under clinical development by Extend Biosciences and currently in Phase II for Hypoparathyroidism. According to GlobalData, Phase II drugs for Hypoparathyroidism have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. EXT-608 overview EXT-607 is under development for the treatment of hypoparathyroidism. It is administered subcutaneously and acts by targeting parathyroid hormone 1 and 2 receptor. The drug candidate is a long-acting version of PTH (1-34) and is developed using D-VITylation platform technology that improves the pharmacokinetic properties of peptides and proteins by fusing with Vitamin-D. Extend Biosciences overview Extend Biosciences is a clinical stage biotechnology company that focuses on the development of a novel drug delivery platform technology. The company’s pipeline products include EXT608 which treats hypoparathyroidism and EXT418 which targets diabetes-induced peripheral neuropathy and cachexia. Extend Biosciences’ D-VITylation platform technology improves the pharmacokinetic properties of peptide- and protein-based therapeutics. The company partners to assist in the discovery, development and commercialization of superior therapeutic peptides and proteins. Biosciences is headquartered in Newton, Massachusetts, the US. For a complete picture of EXT-608’s drug-specific PTSR and LoA scores, This content was updated on 12 April 2024 From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s .Middle East latest: Defense minister acknowledges Israel killed Hamas leader
Should the U.S. increase immigration levels for highly skilled workers?
JuJu Watkins scores 21, No. 6 USC downs Oregon 66-53 in Big Ten openerPort Jervis City Council on Dec. 9 unanimously approved a budget for 2025, with a tax levy increase of around $200,000, or 2.5 percent. The total budget stands at $22.5 million, up by $532,000 from that of the current year. In other words, the city property tax on a single-family house with an assessed value of $50,000 will increase by around $40 in the coming year. For average business owners, their tax rate, or taxes owed per thousand dollars of assessed value, has decreased by nearly 4 percent, meaning many will see a modest reduction in their city tax bills for 2025. That is a direct result of a growing business tax roll in Port Jervis, which includes the continued revitalization of vacant downtown shops and new special franchise charges to utility companies and others, according to city assessor Teresa Spradling in an interview. From 2024 to 2025, the city’s assessed value for business properties and residences with four units or more increased by more than $4 million. In a Dec. 11 interview with The Epoch Times, Mayor Dominic Cicalese said the city has tried its best to hold in tax increases in the face of increased employee expenses under obligated union contracts and more expensive fuels and supplies due to inflation. “The department heads were very modest with their budget requests,“ Cicalese said. ”They understood that we didn’t want to hammer the taxpayers, and they honestly kept their spending in line.” The budget does see a new in-house information technology position, which Cicalese said will help the city cope with the growing cybersecurity challenges. Neither the mayoral position nor the city council posts get a raise next year. Veteran city councilman Stanley Siegal said at the meeting following the budget vote: “I am glad to be able to have voted ‘yes’—my third time in 21 years [on the council] ... 2.5 percent [tax increase] is a doable amount of money. “I would like to thank the mayor, councilman-at-large, and all those people who were involved in the budget this year.” Following the budget vote, Cicalese thanked Stacey Hosking, the new city treasurer and clerk, for her professionalism during his first budget cycle as mayor. As for new initiatives in 2025, Cicalese highlighted to the publication the anticipated upgrade and expansion of the municipal water plant with millions of dollars of incoming state grants.